IDEXX Laboratories, Inc.
IDXX
Pozycja w akcjach
#556
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing,... IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Cena akcji
$557.65
Kapitalizacja rynkowa
$43.93B
Zmiana (1 dzień)
-0.48%
Zmiana (1 rok)
-12.24%
Kraj
US
Handel IDEXX Laboratories, Inc. (IDXX)
Kategoria
Healthcare
Marża operacyjna dla IDEXX Laboratories, Inc. (IDXX)
Marża operacyjna na dzień October 2026 TTM: 32.03%
Według najnowszych raportów finansowych i ceny akcji IDEXX Laboratories, Inc., bieżąca marża operacyjna (TTM) wynosi 32.03%. Na koniec 2024 wynosiła 28.95%.
Historia marży operacyjnej dla IDEXX Laboratories, Inc. od 2000 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 32.03% | 1.36% |
| 2025 | 31.60% | 9.15% |
| 2024 | 28.95% | -3.40% |
| 2023 | 29.97% | 12.29% |
| 2022 | 26.69% | -7.93% |
| 2021 | 28.99% | 12.98% |
| 2020 | 25.66% | 11.71% |
| 2019 | 22.97% | 3.47% |
| 2018 | 22.20% | 5.82% |
| 2017 | 20.98% | 6.34% |
| 2016 | 19.73% | 5.40% |
| 2015 | 18.72% | 6.85% |
| 2014 | 17.52% | -9.55% |
| 2013 | 19.37% | -4.58% |
| 2012 | 20.30% | 4.75% |
| 2011 | 19.38% | 4.87% |
| 2010 | 18.48% | 8.32% |
| 2009 | 17.06% | 1.31% |
| 2008 | 16.84% | 14.09% |
| 2007 | 14.76% | -14.73% |
| 2006 | 17.31% | -4.21% |
| 2005 | 18.07% | -8.13% |
| 2004 | 19.67% | 16.46% |
| 2003 | 16.89% | 5.89% |
| 2002 | 15.95% | 8.87% |
| 2001 | 14.65% | 1.10% |
| 2000 | 14.49% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 17.97% | -99.44% |
US
|
|
| 20.42% | -99.36% |
US
|
|
| -10.70% | -100.33% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -99.31% |
US
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.